CVC  MRL Ventures Fund

     Office Locations:

320 Bent Street, 4th Floor
Cambridge, MA 02141



  • Early
  • Seed



  • Life Sciences & Healthcare



    MRL Ventures Fund is a corporate venture fund for Merck, and is actively developing a portfolio of early-stage therapeutic companies, which are focused on delivering innovative therapies to improve patient care. The fund does not invest in medical devices, diagnostic platforms or digital health. MRL makes seed and early-stage company investments, and seeks to invest up to $15 million per company, providing long-term, and committed capital. MRL will lead or join a syndicate of investors and play an active role on company boards. MRL invests globally and does not ask for any product or technology rights as a condition of investment.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Christine Brennan Partner
    Peter Dudek Partner
    Reza Halse President


    Recent Funding Events (trailing 12 months):







      Entrada Therapeutics



      Series A


      Rheostat Therapeutics



      Series A


      Kymera Therapeutics



      Series B


      Carisma Therapeutics



      Series A


    Portfolio companies include:


    Recent News: